Candidate Gene Targets of the c-Myb Protooncogene in Human Myloid
Reviewer: Walter F. Sall, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 8, 2001
Presenter: Susan E. Shetzline
Institution: University of Pennsylvania
The c-Myb proto-oncogene encoded transcription factor, Myb is
required for normal and malignant hematopoeisis. Ectopic c-Myb expression
can transform hematopoetic cells, thus Myb may play a role in
To identify potential downstream targets of Myb, which may be
targets for future leukemia therapy, K562 cells were engineered to
express an inducible dominant negative form of c-Myb. Downstream gene
induction was assayed using micro-array technique and confirmed using PCR.
10,000 candidate genes were evaluated using this technique.
Materials and Methods
A chimeric transcription actor composed of c-Myb's DNA binding
domain, the engrailed protein transcription repression domain and a
mutated estrogen receptor responsive to tamoxifen was created and stably
transfected into a K562 cell line.
The cells were cultured for 3 days with Tamoxifen, repressing
transcription of myb regulated genes.
These cells were processed for micro-array gene expression
analysis. Confirmation of gene over or under-expression was performed for
several candidate genes using PCR.
Culture of this modified K562 cell line with tamoxifen led to
reduced cell proliferation in-vitro.
Suppression of Myb function led to:
Greater than two-fold over-expression of 34 of 10,000 tested
genes. Several of these, including cdc7 and neuromedin U are associated
with erythroid or megakaryocytic differentiation. Cdc7 and neuromedin U
over-expression was confirmed using PCR.
Greater than two-fold under-expression of 70 genes was found.
Previously identified Myb targets including bcl-2, c-kit, CD34 and
c-myb showed less than 50% change in expression.
It is unclear why dominant negative myb expression slows cell
A manageable number of potential myb regulated genes has been
identified for further analysis.
Neuromedin U and cdc7 overexpression has been confirmed using PCR.
Further investigation into the role of these genes in hematopoetic cell
cycle regulation is ongoing.
This study has identified several new potential molecular targets which
may be important in the pathogenesis of leukemia. Further study of these
downstream targets of c-Myb proto-oncogene expression may yield novel
genetically targeted anti-leukemia therapies in the same mold as STI-571
Jul 23, 2014 - In patients with drug-resistant chronic myeloid leukemia, two second-line drugs -- nilotinib and dasatinib -- may be at least as effective as the front-line drug imatinib, according to research presented this week at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.